Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension

European Respiratory Journal

Volumn 44, Issue 2, 2014, Pages 425-434

  LeVarge, Barbara L ^a   Pomerantsev, Eugene ^b   Channick, Richard N ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; BREATHING; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART ATRIUM ENLARGEMENT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART VENTRICLE SIZE; HUMAN; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PHENOTYPE; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRECAPILLARY PULMONARY HYPERTENSION; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SLEEP DISORDERED BREATHING; AGED; CATHETERIZATION; CLASSIFICATION; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEMODYNAMICS; HYPERTENSION, PULMONARY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONOLOGY; REPRODUCIBILITY; RETROSPECTIVE STUDY; STANDARDS;

AGED; CARDIAC CATHETERIZATION; CATHETERIZATION; CONTINUOUS POSITIVE AIRWAY PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHENOTYPE; POSITIVE-PRESSURE RESPIRATION; PULMONARY MEDICINE; PULMONARY WEDGE PRESSURE; REPRODUCIBILITY OF RESULTS; RESPIRATION; RETROSPECTIVE STUDIES;

EID: 84905660377     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00209313     Document Type: Article

References (45)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
3. Al-Kharrat T, Zarich S, Amoateng-Adjepong Y, et al. Analysis of observer variability in measurement of pulmonary artery occlusion pressures. Am J Respir Crit Care Med 1999; 160: 415-420. (Pubitemid 29380651)
4. Bloomfield RA, Lauson HD, Cournand A, et al. Recording of right heart pressures in normal subjects and in patients with chronic pulmonary disease and various types of cardio-circulatory disease. J Clin Invest 1946; 25: 639-664.
5. Cournand A, Motley HL, Werko L, et al. Physiological studies of the effects of intermittent positive pressure breathing on cardiac output in man. Am J Physiol 1948; 152: 162-174.
6. Segel N, Hudson WA, Harris P, et al. The circulatory effects of electrically induced changes in ventricular rate at rest and during exercise in complete heart block. J Clin Invest 1964; 43: 1541-1550.
7. Harris P. Influence of acetylcholine on the pulmonary arterial pressure. Br Heart J 1957; 19: 272-278.
8. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary HypertensionA Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
9. Ahrens TS, Schallom L. Comparison of pulmonary artery and central venous pressure waveform measurements via digital and graphic measurement methods. Heart Lung 2001; 30: 26-38. (Pubitemid 32108152)
10. Ryan JJ, Rich JD, Thiruvoipati T, et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 2012; 163: 589-594.
11. Maran AG. Variables in pulmonary capillary wedge pressure: variation with intrathoracic pressure, graphic and digital recorders. Crit Care Med 1980; 8: 102-105.
12. Cengiz M, Crapo RO, Gardner RM. The effect of ventilation on the accuracy of pulmonary artery and wedge pressure measurements. Crit Care Med 1983; 11: 502-507. (Pubitemid 13077920)
13. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009; 136: 37-43.
14. Hoyt JD, Leatherman JW. Interpretation of the pulmonary artery occlusion pressure in mechanically ventilated patients with large respiratory excursions in intrathoracic pressure. Intensive Care Med 1997; 23: 1125-1131. (Pubitemid 27517318)
15. Schuster DP, Seeman MD. Temporary muscle paralysis for accurate measurement of pulmonary artery occlusion pressure. Chest 1983; 84: 593-597. (Pubitemid 14228972)
16. Behazin N, Jones SB, Cohen RI, et al. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. J Appl Physiol 2010; 108: 212-218.
17. Boerrigter B, Trip P, Bogaard HJ, et al. Right atrial pressure affects the interaction between lung mechanics and right ventricular function in spontaneously breathing COPD patients. PLoS One 2012; 7: e30208.
18. Butler J, Schrijen F, Henriquez A, et al. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138: 350-354.
19. Rice DL, Awe RJ, Gaasch WH, et al. Wedge pressure measurement in obstructive pulmonary disease. Chest 1974; 66: 628-632.
20. Boerrigter BG, Waxman AB, Westerhof N, et al. Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. Eur Respir J 2014; 43: 1316-1325.
21. Naeije R, Boerrigter BG. Pulmonary hypertension at exercise in COPD: does it matter? Eur Respir J 2013; 41: 1002-1004.
22. Pinsky MR. Cardiovascular issues in respiratory care. Chest 2005; 128: Suppl. 5, 592S-597S. (Pubitemid 41692554)
23. Lauson HD, Bloomfield RA, Cournand A. The influence of the respiration on the circulation in man; with special reference to pressures in the right auricle, right ventricle, femoral artery and peripheral veins. Am J Med 1946; 1: 315-336.
24. Bahler RC, Chester EH, Belman MJ, et al. Multidisciplinary treatment of chronic pulmonary insufficiency. 4. The influence of intrathoracic pressure variations on increases in pulmonary vascular pressure during exercise in patients with chronic obstructive pulmonary disease. Chest 1977; 72: 703-708. (Pubitemid 8253634)
25. Lim TP, Brownlee WE. Pulmonary hemodynamics in obstructive lung disease. Dis Chest 1968; 53: 113-125.
26. Steier J, Jolley CJ, Seymour J, et al. Neural respiratory drive in obesity. Thorax 2009; 64: 719-725.
27. Pankow W, Podszus T, Gutheil T, et al. Expiratory flow limitation and intrinsic positive end-expiratory pressure in obesity. J Appl Physiol 1998; 85: 1236-1243. (Pubitemid 28465047)
28. Frost AE, Farber HW, Barst RJ, et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mmHg: insights from the REVEAL Registry. Chest 2013; 143: 185-195.
29. Oliveira RK, Ferreira EV, Ramos RP, et al. Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension. J Heart Lung Transplant 2014; 33: 157-162.
30. Bitar A, Selej M, Bolad I, et al. Poor agreement between pulmonary capillary wedge pressure and left ventricular end-diastolic pressure in a veteran population. PLoS One 2014; 9: e87304.
31. Kovacs G, Avian A, Olschewski A, et al. Zero reference level for right heart catheterisation. Eur Respir J 2013; 42: 1586-1594.
32. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123. (Pubitemid 32971843)
33. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
34. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157. (Pubitemid 41653106)
35. Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183: 1723-1729.
36. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263. (Pubitemid 44924827)
37. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329. (Pubitemid 34815354)
38. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903. (Pubitemid 34984638)
39. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804. (Pubitemid 34229650)
40. Zeng WJ, Xiong CM, Zhao L, et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J 2012; 40: 67-74.
41. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
42. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
43. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110. (Pubitemid 351194756)
44. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301. (Pubitemid 26033085)
45. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.